HOME >> BIOLOGY >> NEWS
New Hope On The Horizon For Patients With End-Stage Cardiovascular Disease

LOS ANGELES (August 3, 1998) -- Two experimental protocols are now available at Cedars-Sinai Medical Center for patients who have undergone multiple angioplasties or bypass procedures for coronary artery disease. Both procedures are non-surgical and show promise of improving quality of life for patients with end-stage cardiovascular disease. "The preliminary data are very encouraging," says P.K. Shah, M.D., Director of Cardiology at Cedars-Sinai.

Percutaneous Transmyocardial Laser Revascularization (PTMR)
According to Dr. Shah, Cedars-Sinai is one of only a few sites in the nation to offer Percutaneous Transmyocardial Laser Revascularization (PTMR). Using this procedure, cardiologists insert a laser catheter into the heart, creating multiple channels from the inside of the heart, out. These channels improve blood flow to heart muscles and stimulate growth of new blood vessels. To date, four patients have undergone PTMR at Cedars-Sinai. Norman Lepor, M.D., is the Principal Investigator on this study.

Vascular Endothelial Growth Factor Therapy (VEGF)
The second experimental protocol is Vascular Endothelial Growth Factor (VEGF) Therapy. VEGF is a genetically engineered compound that is normally produced in small amounts by the body and stimulates blood vessel growth. In this procedure, it is injected directly into the coronary artery to further stimulate blood vessel growth. The initial injection is followed by a series of three intravenous infusions -- one every three days. These subsequent infusions are done on an outpatient basis and take about four hours each. To date, two patients have been treated with VEFG Therapy at Cedars-Sinai. Dr. Shah is the Principal Investigator on this study.

# # #

To arrange an interview, please call 1-800-396-1002. Reporters, please note that this telephone number is exclusively for media use. Thank you for not publishing it.


'"/>

Contact: Sandy Van or Roberta Nichols
sandy@vancommunications.com
1-800-396-1002
Cedars-Sinai Medical Center
3-Aug-1998


Page: 1

Related biology news :

1. Bacteria Becoming Increasingly Resistant To Antibiotics, But New Vaccines Are On The Horizon
2. Patients cells from tumors, the immune system merged for customized cancer therapy
3. Patients give nod to kidney dialysis at home
4. Patients with atrial fibrillation undertreated for stroke risk
5. Patients with serious kidney disorder produce natriuretic peptides at above average rates
6. Drug treatment interruptions boost immune response to HIV in Patients
7. Study Suggests Vaccine Increases Survival In Ovarian And Breast Cancer Patients Following High-Dose Chemotherapy And Autologous Stem Cell Transplant
8. GenRISK Genetic Testing Program At Cedars-Sinai Medical Center Offers Patients New Hope In Confronting Disease
9. Oregon Scientists Discover A Second Blood-Brain Barrier; Important Finding For Patients With Brain Cancers And Neurological Disorders
10. In Colorado States Veterinary Foal Care Program, Student Volunteers Provide All-Night Care For Sick And Very Needy Patients
11. AIDS Virus May Evolve Differently In Cerebrospinal Fluid Compared With Blood In Some Patients, UCSF/Gladstone Research Finds

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/6/2019)... ... ... Keck Graduate Institute (KGI) President Sheldon Schuster has announced Martin Zdanowicz as the ... is highly regarded as an innovative leader who prioritizes student success and faculty development,” ... build on the success of the KGI School of Pharmacy and Health Sciences.” , ...
(Date:8/1/2019)... ... August 01, 2019 , ... The GENSPEED platform is a compact, fast and ... fully developed with over 100 units deployed in the field for multiple applications. ... collaboration with axiVEND will give us a foothold in the USA to better support ...
(Date:8/1/2019)... ... 2019 , ... USDM Life Sciences (USDM) announces that Jay Crowley, Vice President ... addressing challenges with the upcoming EU MDR IVDR regulations . , ... variety of positions over his 26 years at the FDA, including developing the framework ...
Breaking Biology News(10 mins):
(Date:6/18/2019)... YORK and SOMERSET, N.J. (PRWEB) , ... June ... ... Catalent Biologics, today announced that they have entered into an agreement for production ... product candidates, IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) ...
(Date:6/12/2019)... EGG HARBOR TOWNSHIP, N.J. (PRWEB) , ... June ... ... premier manufacturer of custom built, helium-based leak testing instruments for the Pharmaceutical, Biotechnology, ... partnership agreement with Shanghai Zillion has been signed. The agreement will grant exclusive ...
(Date:6/11/2019)... ... June 10, 2019 , ... ... in an upcoming episode, scheduled to broadcast 4Q/2019. Check your local listings for ... will educate viewers about how its technology facilitates laboratories to improve efficiency and ...
(Date:6/11/2019)... ... June 11, 2019 , ... Mytonomy, the ... national leader in opioid treatment, announced today they are partnering to combat the ... recently deployed its virtual care platform at the Mayo Clinic to drive shared ...
Breaking Biology Technology:
Cached News: